Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Histologically confirmed CLL or SLL as defined by the following:~* B-lymphocytosis greater than 5000 cells/micro L (may be less than 5000 cells/micro L if lymphadenopathy is present with histologic confirmation of lymph node involvement by SLL).~* Immunophenotypic profile consistent with CLL as demonstrated by flow cytometry~* Appropriate immunophonotype (CD5/19/23+)~* Clonality of lymphocytosis confirmed by flow cytometry~* large lymphocytes less than 55 % of blood lymphocytes~Active disease as defined by at least one of the following:~* Weight loss greater than or equal to10 percent within the previous 6 months~* Extreme fatigue~* Fevers of greater than 100.5 degree F for greater than or equal to 2 weeks without evidence of infection~* Night sweats for more than one month without evidence of infection~* Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia~* Massive or progressive splenomegaly~* Massive nodes or clusters or progressive lymphadenopathy~* Progressive lymphocytosis with an increase of greater than 50% over a 2 month period, or an anticipated doubling time of less than 6 months 0~Measurable disease (defined as two dimensional disease on imaging or quantifiable leukemic disease).~Ages 18 and over.~EXCLUSION CRITERIA:~Prior monoclonal antibody therapy with agents having anti-CLL activity~Prior cytotoxic chemotherapy with agents having anti-CLL activity (Fludarabine, Cyclophosphamide, Bendamustine, Chlorambucil)~Transformed CLL~Active autoimmune hemolytic anemia or thrombocytopenia~Any medical condition that requires the chronic use of corticosteroids~Active or latent Hepatitis B infection~HIV infection~Severe chronic obstructive pulmonary disease, severe cardiac disease, or other uncontrolled medical condition that would, in the opinion of the principal investigator, place the subject at an unreasonable risk of life-threatening adverse events due to chemoimmunotherapy~ECOG performance status 3 or worse~Creatinine greater than or equal to 2 mg/dL or creatinine clearance less than or equal to 30 mL/min~Bilirubin greater than or equal to 2 mg/dL or active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator assessment)~Female patients: Current pregnancy or unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential or currently breastfeeding. Male patients who are unwilling to follow the contraception requirements described in this protocol.~Psychiatric illness/social situations that would limit the patient s ability to tolerate and/or comply with study requirements.~Unable to understand the investigational nature of the study or give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- FO Arm (fludarabine and ofatumumab) (Type: EXPERIMENTAL): For patients with non-high risk FISH changes
- FCO Arm (fludarabine, cyclophosphamide, and ofatumumab) (Type: EXPERIMENTAL): For patients with high risk FISH changes

Based on this trial design, predict the completion outcome and termination type (if applicable).